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Multiple myeloma is an incurable disease, although patient survival has increased with the availability of novel agents. Both
multiple myeloma and its therapies often aﬀect the renal, immune, skeletal, hematologic, and nervous systems. The resulting
organ dysfunctions often impair the quality of life of aﬀected patients, complicate and limit subsequent therapies, and may result
in signiﬁcant mortality. Research on the treatment of complications of multiple myeloma has been limited; hence, preventative
and management strategies for patients with these complications are heterogeneous and often based on anecdotal experience. In
this paper, we review the eﬀects of myeloma and the novel therapies on organ systems and suggest management strategies.
1.Introduction
The past decade has witnessed signiﬁcant advances in
the treatment of multiple myeloma with the introduction
of high-dose therapy and stem cell transplantation into
routine clinical practice, as well as the approval by the
Food and Drug Administration (FDA) of four therapeutic
agents, namely, lenalidomide, thalidomide, bortezomib, and
pegylated liposomal doxorubicin, with each demonstrating
survival beneﬁt in patients with the disease [1–4]. Despite
the improved survival of patients, the disease remains
uniformly fatal [5]. In addition, the era of novel agents
has been marked by the emergence of newer toxicities
and complications associated with therapy and long-term
survivorship. These complications frequently diminish the
quality of life of patients, complicate and limit further
therapy for the disease, and can result in mortality. Little
research has been performed in this area, and many of the
recommendations have been historically based on anecdotal
data and expert opinions.
This review article focuses on ﬁve organ systems most
commonly aﬀected by multiple myeloma and its treatments,
namely, the renal, immune, thromboembolic, skeletal, and
peripheral nervous systems. In addition, we discuss man-
agement strategies to improve upon supportive therapies in
treating patients with multiple myeloma.
2.Renal Dysfunction:
Etiologies andManagement
Renal failure is a frequent ﬁnding in patients with multiple
myeloma, aﬀecting as many as 50% of patients during the
course of the disease and approximately 20% at diagnosis
[6]. Renal failure can be secondary to the myeloma para-
protein (such as in cast nephropathy, amyloidosis, and light
chain deposition disease) or related to complications of
the disease (hypercalcemia, secondary to often used drugs
such as bisphosphonates, nonsteroidal antiinﬂammatory
drugs, intravenous contrast, or aminoglycosides, or prerenal
azotemia) [7]. Nonparaprotein causes of renal insuﬃciency
are not discussed here and are beyond the scope of this
review. Accordingly, the etiology of renal failure in this
setting may be diﬃcult to establish, but kidney biopsy could2 Advances in Hematology
sometimes be helpful in delineating the future care of these
patients.
Cast nephropathy is the most frequent cause of para-
protein renal disease in patients with myeloma, accounting
for two-thirds of those with this disease [8]. Cast formation
usually occurs in the distal nephron due to the precipitation
of light chain with Tamm-Horsfall proteins. This results in
damage to the renal epithelium, allowing passage of the
light chains into the interstitium and causing inﬂammation
and ﬁbrosis [9]. Additionally, endocytosis of the light
chains in the proximal tubules triggers activation of nuclear
factor-κB, (NF-κB), which in turn leads to the synthesis
and activation of inﬂammatory signaling pathways such as
mitogen-activated protein kinase, extracellular signal-related
kinase, and Jun N-terminal kinase pathways, all causing
further inﬂammation and ﬁbrosis [10]. One group observed
that a vasoactive intestinal peptide could inhibit this process.
These researchers showed that this peptide inhibited light
chain-induced renal production of IL-6 and TNF-α in rats
and light chain-induced renal epithelial injury in vitro,
thus suggesting possible future application for myeloma
renal disease [11]. In rare cases, crystal deposition in the
tubules can result in severe and rapid renal failure, a process
known as “crystal nephropathy,” which portends a poorer
prognosis [8, 12]. Current therapy for cast nephropathy
involves treatment of the underlying myeloma with or
without plasmapheresis, which can often lead to reversal
of cast nephropathy if therapy is instituted early [13]. The
role of plasmapheresis in cast nephropathy is controversial.
Two small single institution studies randomized patients
withbiopsy-provencastnephropathy,andnotedasigniﬁcant
improvement in renal disease (and in survival in one
study) with plasmapheresis [13, 14]. A larger multi-center
Canadian study suggested no signiﬁcant improvement in
renal function with plasmapheresis in an unselected group
of myeloma patients with renal failure [15]. The European
trial of free light chain removal by extended hemodialysis
(EuLITE) is currently investigating the beneﬁt of removing
circulating free light chains by hemodialysis in patients with
cast nephropathy using two Gambro HCO 1100 dialyzers in
series [16].
Primary systemic amyloidosis represents another cause
of renal dysfunction in patients with myeloma. In renal amy-
loidosis,theimmunoglobulinlightchainﬁbrilsaredeposited
in the mesangium of kidneys, resulting in proteinuria and
nephrotic syndrome [17]. The diagnosis of amyloidosis
requires the demonstration of apple green birefringence on
Congo red staining of involved tissue. Immunostain for
kappa or lambda light chain and electron microscopy are
important adjunctive conﬁrmatory tests. Systemic amyloi-
d o s i sc a no f t e nb ed i a g n o s e db yal e s si n v a s i v em e t h o dv i a
fat pad biopsy. Patients with concomitant primary (AL)
amyloidosis and myeloma tend to have poorer prognosis,
due to the additional adverse eﬀects that AL amyloidosis
may have on other major organs such as the heart, nervous
system, gastrointestinal system, and kidneys [18]. Treatment
of renal amyloidosis is aimed at controlling the plasma cell
disorder using chemotherapy, targeted agents, and stem cell
transplantation as indicated [19–21].
Light chain deposition disease, ﬁrst described in 1976
by Randall et al. [22], involves deposition of monoclonal,
amorphous, nonCongophilic light chain immunoglobulins
in various organs in the body, most commonly the kidneys.
The rates of incidence of this disease in autopsies of patients
with myeloma range from 5% to 11% [23]. The majority of
patients have kappa light chain deposition. Although most
patients with this disease have an identiﬁable monoclonal
protein in the serum and/or urine, 25% of patients have
no detectable monoclonal light chain by standard testing,
and free light chain assays may be helpful [24]. Renal
involvement results in renal insuﬃciency, proteinuria, and
nephrotic syndrome from the light chain deposits in the
mesangium, thereby forming nodular lesions (that may
mimic diabetic nephropathy under light microscopy). In
addition, associated tubular thickening or atrophy may also
be noted. Immunoﬂuorescence helps to diﬀerentiate these
nodular lesions from diabetic lesions, but renal biopsy is
required for diagnosis [25, 26]. The goal of therapy involves
treating the underlying plasma cell dyscrasia. Often, renal
recovery is not seen. For patients who have severe renal
failure,renaltransplantationcanbeconsidered,althoughfew
reports support this practice.
Insummary,identifyingtheetiologyofrenaldysfunction
in patients with multiple myeloma can be diﬃcult but is of
importance and often steers management decisions.
3. Infectious Complications and Prophylaxis
Multiple myeloma results in an immunodeﬁcient state with
dysfunctions in both the cellular and the humoral immune
system. Hypogammaglobulinemia, T-cell dysfunction, and
granulocytopenia (secondary to marrow involvement and
therapy) result in increased infectious complications, with
bacterial infections (encapsulated organisms) being the most
common and resulting in a high mortality and morbidity.
Bacterial infections are twice as likely during active therapy
and during induction therapy (a rate of 3 infections per
year compared to 1.5 infections per year, resp.) [27]. In
addition, treatment with high-dose dexamethasone-based
regimens is associated with a higher rate of severe infections
and induction death compared to regimens containing lower
dose dexamethasone (16% versus 7%, resp.) [28]. Primary
prophylaxis with antibiotics is occasionally recommended,
depending on the intensity of the induction regimen. In
one study, a signiﬁcant reduction in infectious complications
(absolute rate of reduction of 88%) occurred with the use
of trimethoprim- sulfamethoxazole for the ﬁrst 2 months of
induction chemotherapy [27]. Fluoroquinolones are other
commonly used prophylactic antibiotics with some multi-
agent induction regimens. Routine use of antifungal agents
with commonly prescribed induction regimens are not rec-
ommendedbecauseoftherelativelylowincidenceofinvasive
fungal infections despite corticosteroid therapy. Varicella
zoster virus reactivation has been reported in bortezomib-
treated patients, although routine use of acyclovir or valacy-
clovir (at prophylactic doses) has been found to be eﬀective
at reducing this risk [3, 29].Advances in Hematology 3
Another prophylactic strategy involves the use of intra-
venous immunoglobulins in patients with hypogamma-
globulinemia and recurrent infections. This practice is
supported by a randomized controlled clinical trial in 82
patients with stable multiple myeloma, comparing intra-
venous immunoglobulins (0.4g/kg monthly for 1 year) to
placebo. This trial noted no episode of pneumonia and
septicemia in the treatment group compared to 10 such
episodes in the placebo group [30].
Vaccine-induced speciﬁc immunity is suspected to be
unreliable in myeloma patients. Because of the lack of
studies in this patient population, there are no speciﬁc rec-
ommendations and data regarding vaccination eﬀectiveness
in multiple myeloma patients. Despite reports suggesting
a decreased immunogenicity [31] of pneumococcal and
inﬂuenza vaccines in multiple myeloma patients, the risk-to-
beneﬁt ratio favors recommending these vaccines, although
monitoring of postvaccination titers is generally not recom-
mended. Recently, one study noted a higher eﬀectiveness
of pneumococcal vaccination in multiple myeloma patients
treated with lenalidomide (an immune modulator) [32]. In
2008, the FDA approved the use of a varicella zoster virus




4. Medicaland SurgicalManagement of
Bone Disease
Myeloma bone disease is characterized by an increase in
bone resorption over bone formation, resulting in lytic
lesions and osteoporosis. Thus, patients have a propensity
for fractures (most commonly in the vertebral spine). The
pathophysiology of myeloma bone disease involves the
receptor activator nuclear factor-κB( R A N K ) ,w h i c hc o n t r o l s
osteoclastic activation. The RANK ligand (RANKL) and a
regulatory protein, osteoprotegerin, produced by stromal
cells both bind RANK. Osteoprotegerin is a mimic for
RANKL and inhibits signaling of the RANK-RANKL com-
plex. Myeloma cells upregulate RANKL and downregulate
osteoprotegerin, resulting in increased osteoclastic activity.
This upregulation occurs through cytokine signaling of IL-6,
TNF-β, and insulin-like growth factor (IGF), all of which are
increased due to interaction of myeloma cells with stromal
cells (Figure 1). In addition, DKK1, an inhibitor of Wnt, has
been found to be important in osteoblastic cell growth and
diﬀerentiation. Monoclonal antibodies targeting DKK1 are
currently the subject of investigations [35].
To determine the severity of disease and to identify com-
plications during and before treatment, assessment of bony
involvement is required at diagnosis. Up to 80% of myeloma
patientsatdiagnosisarenotedtohaveabnormalitiesonplain
radiographs. This is usually in the form of punched-out lytic
lesions, but vertebral compression fractures are also noted
in about half of the patients [36]. A baseline skeletal survey,
with plain radiographs of the skull, ribs, pelvis, spine, and
long bones, should be performed in all patients at diagnosis,
with most experts recommending a yearly skeletal survey
in patients with active disease. For patients suspected of
having active disease, magnetic resonance imaging of the
spine at diagnosis is strongly suggested. However, magnetic
resonance imaging is generally mandated for patients with
signiﬁcant back pain to rule out cord compromise [37]. The
role of positron emission tomography is not well established,
but some investigators have reported the test’s usefulness in
patients with extramedullary and bone plasmacytomas [38].
Radionuclide bone scans are generally not useful because
the lesions commonly seen in myeloma patients are purely
osteolytic and do not generate signiﬁcant uptake on bone
scans [39].
In addition to optimal medical pain control, nonsurgical
management of myeloma bone disease includes the use
of the antiresorptive bisphosphonates, physical therapy,
rehabilitation exercises, as well as judicious use of radiation
therapy.
Bisphosphonates have been shown to inhibit the pro-
liferation and diﬀerentiation of osteoclasts with resultant
osteoclast apoptosis [40]. Although preclinical studies have
suggested an antineoplastic eﬀect of bisphosphonates, this
has not been substantiated in clinical studies. A large double-
blind randomized study demonstrated that pain and bone-
related complications were reduced and performance status
and quality of life were improved in myeloma patients with
lytic lesions treated with monthly intravenous pamidronate
[41, 42]. Zoledronic acid, which has been found to be
equally eﬃcacious as pamidronate, can be administered over
a shorter period of time than that for pamidronate [42].
Althoughtheseagentsaregenerallywelltolerated,sideeﬀects
of therapy occasionally limit their use. Acute complications
include ﬂu-like symptoms (related to the ﬁrst infusion),
renal toxicity (with a decrease in incidence with longer
infusion duration), and osteonecrosis of the jaw, which
occurs in approximately 5% of multiple myeloma patients
on chronic monthly bisphosphonate therapy. The incidence
of osteonecrosis of the jaw can be decreased with attention
to dental hygiene, by delaying therapy until after certain
dental procedures, and with less frequent bisphosphonate
administration [43, 44]. An American Society of Clinical
Oncology expert panel recommends that myeloma patients
who have at least one lytic lesion be treated with intravenous
pamidronate (90mg over 2 hours) or zoledronic acid (4mg
over 15–30 minutes) every 3-4 weeks for the ﬁrst 12 months.
Thereafter, therapy should be individualized based on the
patient’s risk of a skeletal event [45]. Another antiresorptive
therapy involving the inhibition of RANKL by a monoclonal
antibody (denosumab) is currently the subject of clinical
investigations [46]. In addition, novel myeloma therapies,
including lenalidomide and bortezomib, have been demon-
strated to result in beneﬁcial eﬀects on bone metabolism in
multiple myeloma patients [47, 48].
Multiplemyelomacellsareexquisitelyradiosensitive,and
radiation therapy is eﬀective in the treatment of localized
bone complications, especially in cases of epidural disease
or cord compression. Concerns over compromised marrow
reserve and the availability of novel and more eﬀective



























Figure 1: Pathophysiology of myeloma bone disease. Black arrows indicate increased production or activation, and red arrows indicate
decreased production or inhibition. Normal bone metabolism involves the constant rebuilding of bone by osteoblasts and resorption of
bone by osteoclasts, intricately balanced through appropriate cytokine signaling (usually associated with an increased OPG to RANKL
ratio). The presence of myeloma cells in the bone marrow milieu results in upregulation of osteoclastic activity compared with osteoblastic
bone formation resulting in lytic lesions. The malignant plasma cells interact with stromal cells, causing increased cytokine signaling
through IL-6 and TNF-β. This results in increased RANKL expression by bone marrow stromal cells, stimulation of plasma cell growth,
and drug resistance. In addition, malignant plasma cells produce inhibitors of Wnt signaling (DKK1 and sFRPs). Wnt inhibition results in
downregulation of OPG production and upregulation of RANKL. The interaction of RANK with its ligand (RANKL) leads to osteoclast
activation via signaling by NF-κB. In addition, malignant plasma cells produce MIP-1α, which directly stimulates osteoclasts. Therapy with
bisphosphonates results in osteoclast inhibition and osteoblast activation. The novel monoclonal antibody, denosumab, which neutralizes
RANKL, is currently the subject of clinical investigations for bone disease therapy in patients with multiple myeloma. MM: multiple
myeloma, IL-6: interleukin 6, VEGF: vascular endothelial growth factor, TNF-α: tumor necrosis factor-α, BMSC: bone marrow stromal
cell, MIP-1α: macrophage inhibitory protein-1α, OB: osteoblast, OC: osteoclasts, OPG: osteoprotegerin, DKK1: dickkopf, sFRPs: serum
frizzle related proteins, VCAM-1: vascular cell adhesion molecule-1, RANK: receptor activator for nuclear factor κB, JunN: c-Jun N-terminal
protein kinase, Wnt, Wnt glycoproteins (bind to sFRPs).
Little is known about the eﬀect of an exercise program
on patients with multiple myeloma. Although a retrospective
study suggested that exercise had a positive eﬀect on quality
of life [49], bias is likely with such studies, and the type,
intensity, and duration of the optimal exercise program have
yet to be deﬁned. In our experience, we have anecdotally
noted aquatic therapy to be eﬀective in improving mobility
while being well tolerated by myeloma patients. Despite
occasional reports noting the eﬀectiveness of acupuncture
in patients with uncontrolled pain, controlled trials have
not been performed, and the use of complementary and
alternativemedicinecannotberoutinelyrecommended[50].
Surgical intervention is at times necessary for the pre-
vention and treatment of fractures. More recently, patients
with painful vertebral compression fractures can be treated
with vertebroplasty or balloon kyphoplasty. Vertebroplasty
involves injection of poly-methylmethacrylate bone cement
in the vertebral body. In one study, pain control was
improved in 97% of the patients with the use of this
procedure. The incidence of serious complications (such
as cement leak) ranges from 1%–3% [51, 52]. Balloon
kyphoplasty involves the insertion of an inﬂatable balloon in
the vertebral body, which is then ﬁlled with bone cement. In
addition to pain control, height restoration can be achieved
with this procedure, and in some centers this procedure is
preferred over vertebroplasty [53, 54]. Unanswered clinical
problems include the utility and timing of intervention
in patients with asymptomatic or minimally symptomatic
vertebral fractures.
Lytic lesions involving weight-bearing long bones may
occasionally require prophylactic surgical ﬁxation with
intraosseous rods and/or pins. The location of the lyticAdvances in Hematology 5
lesion, degree of cortical destruction, and the impact on
patients’ mobility and limb function are all taken into
consideration for guiding the appropriate surgical interven-
tion [55]. In general, we recommend surgical evaluation
by an oncologic orthopedic surgeon for patients who have
lytic lesions exhibiting greater than 50% cortical destruc-
tion of a weight-bearing long bone or pain with weight
bearing.
5. Thromboembolic Events
Patients with monoclonal gammopathy of undetermined
signiﬁcance and multiple myeloma are at increased risk of
venous thromboembolic events with a baseline prevalence
of approximately 10% [56]. Patients with newly diagnosed
multiple myeloma are at higher risk of thromboembolic
events than patients with relapsed multiple myeloma, pos-
sibly a reﬂection of increased burden of disease. In addition,
immunomodulatory drugs (lenalidomide and thalidomide)
have been linked to increased thromboembolic events,
especially in combination with high-dose corticosteroids
and anthracycline chemotherapy [57–59]. Vascular access
devices, fractures or immobilization, and decreased perfor-
mance status all contribute to this increased rate of venous
thromboembolic events. The coagulopathy associated with
multiple myeloma and monoclonal gammopathy remains
poorly understood. Some investigators have suggested that
acquired protein C resistance [60], increased factor VIII
levels, and abnormal platelet aggregation studies [57]m a yb e
contributory;however,theprecisemechanismandcontribu-
tion of each of these ﬁndings remain unclear.
For all multiple myeloma patients receiving therapy with
immunomodulatoryagents(lenalidomideandthalidomide),
primary prophylaxis for venous thromboembolic events is
recommended. The prophylactic strategy of choice is often
based on the clinical situation and the presence of addi-
tional thrombophilic risk factors [61]. Recently, Palumbo
et al. [61] randomized newly diagnosed multiple myeloma
patients receiving thalidomide-based induction to low-dose
aspirin (100mg daily), prophylactic low molecular weight
heparin (Enoxaparin 40mg SC daily), or ﬁxed-dose warfarin
(1.25mg daily orally) [62]. This group found that rates
of venous thromboembolic events and clinically signiﬁcant
bleeding were low overall with all three strategies. We
recommend the use of low-dose aspirin in low-risk patients
treated with immunomodulatory agents due to cost and ease
of administration concerns [62].
Patients who develop a venous thromboembolic event
while receiving therapy with immunomodulatory drugs
will require therapeutic anticoagulation with low molecu-
lar weight heparin or unfractionated heparin followed by
warfarin. Therapy with the immunomodulatory drug can
be resumed once the patient has been fully anticoagulated
and usually should be continued for as long as the patient




6. Management of Neuropathy
Patients with multiple myeloma develop peripheral neu-
ropathy as a result of the disease itself, secondary to ther-
apeutic agents (bortezomib, thalidomide, vincristine), and
secondary to metabolic/nutritional deﬁciencies (e.g., cobal-
amin deﬁciency) [63]. Myeloma-related neuronal injury
can be secondary to neuronal inﬁltration (as in amyloid
deposition or light chain deposition disease), with neu-
ronal compression causing radiculopathy, hyperviscosity,
cryoglobulinemia, uremia, and autoimmune pathology [64].
Bortezomib-related peripheral neuropathy typically occurs
during therapy but has also been noted to occur or worsen
soon after discontinuation of therapy [65]. In addition,
autonomic neuropathy has been reported in this setting,
which then represents a therapeutic challenge. Neuropa-
thy from bortezomib is frequently painful, resulting in
dose modiﬁcations and interruption of therapy in many
patients. Guidelines for bortezomib dose modiﬁcations due
to peripheral neuropathy have been recently reviewed [66].
Most patients in a recent large randomized trial treated
with bortezomib-based therapy experienced improvement
of neuropathy on average 1.9 months after discontinuing
therapy, and 60% of patients had resolution of symptoms
on average 5.9 months later [29]. Thalidomide-induced
peripheral neuropathy is often related to the total cumu-
lative dose of the drug; after 12 months of thalidomide
therapy, about 70% of patients will develop neuropathy.
Unlike bortezomib, the majority of these patients develop
grade 1-2 neuropathy versus grade 3-4 in the bortezomib
patients, and the thalidomide-induced neuropathy is often
permanent [67]. Clinical symptoms include predominantly
sensory manifestations such as parestheses and hyperesthe-
sia. Patients may also develop autonomic dysfunction and
motor symptoms. Elderly patients are more prone to the
developmentofneurotoxiceﬀects[62].Lenalidomide,onthe
other hand, is considered less neurotoxic than thalidomide
and has not been reported to result in severe neuropathy
[68]. More recently, newer proteasome inhibitors, such as
carﬁlzomib, have been shown to be less neurotoxic than
bortezomib [69].
Often, the ﬁrst step in the evaluation of patients with
neuropathy is to exclude urgent potentially reversible eti-
ologies (such as cord compression). In addition, low cobal-
amin levels have been frequently observed in patients with
monoclonal gammopathy and multiple myeloma, and this
etiology should be readily identiﬁed and treated [70]. For
patients who have drug-induced neuropathy, early identiﬁ-
cationanddosemodiﬁcationarenecessary.Myeloma-related
neuropathy may improve with therapy, although it seldom
resolves. The mainstay of symptomatic treatment has been
extrapolated from the treatment used in diabetic patients,
which includes antidepressants (amitriptyline, duloxetine),
antiepileptics (carbamazepine, gabapentin, pregabalin), and
opiates for pain control [71, 72]. In addition, experts have
suggested anecdotal beneﬁts with the use of dietary sup-
plements and high-dose vitamins and amino acids (such as
L-glutamine, carnitine, coenzyme Q), but these approaches
have not been formally evaluated in this setting.6 Advances in Hematology
Neuropathyinpatientswithmultiplemyelomacanresult
in signiﬁcant disability and impairment in quality of life.
Earlyidentiﬁcationandmanagementcanoftensparepatients
severe toxicity and dysfunction.
In conclusion, multiple myeloma is a complex disease
having a number of complications and therapeutic chal-
lenges. The cure for this disease remains evasive. Although
novel therapeutic strategies have resulted in improved
patient survival, supportive therapy continues to be an
essentialcomponentintreatingcomplicationsofthisdisease.
Therefore, further research to evaluate and improve upon
existing supportive therapies in multiple myeloma is needed,
as this is an important adjunct in the everyday care of
patients with this disease.
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